Search research articles
Contact Us
Filters
Showing results (111-120 of 211) with videos related to
Page
of 22
Sort By:
Human Vaccines & Immunotherapeutics
|
October 4, 2012
A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years
Timo Vesikari, Aino Forstén, Dominique Boutriau, et al.
Vaccine
|
November 26, 2018
Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers
Timo Vesikari, Ray Borrow, Xavier Da Costa, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
November 15, 2011
Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial
Timo Vesikari, Jiri Beran, Serge Durviaux, et al.
The Pediatric Infectious Disease Journal
|
May 10, 2011
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants
Timo Vesikari, Jason C Martin, Charles L Liss, et al.
Human Vaccines & Immunotherapeutics
|
March 25, 2017
Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa
Timo Vesikari, Luis Rivera, Tiina Korhonen, et al.
Human Vaccines & Immunotherapeutics
|
September 19, 2019
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
Timo Vesikari, Miia Virta, Seppo Heinonen, et al.
The Pediatric Infectious Disease Journal
|
May 5, 2011
Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age
Timo Vesikari, Aino Karvonen, Tiina Korhonen, et al.
Vaccine
|
October 16, 2007
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres
Clare L Hibbert, Pedro A Piedra, Kimmie K McLaurin, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2010
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months
Timo Vesikari, Aino Karvonen, Niklas Lindblad, et al.
Lancet (London, England)
|
January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
Timo Vesikari, Susanna Esposito, Roman Prymula, et al.
Page
of 22
Search research articles
Search
Showing results (111-120 of 211) with videos related to
Sort By:
Page
of 22
Human Vaccines & Immunotherapeutics
|
October 4, 2012
A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years
Timo Vesikari, Aino Forstén, Dominique Boutriau, et al.
Vaccine
|
November 26, 2018
Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers
Timo Vesikari, Ray Borrow, Xavier Da Costa, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
November 15, 2011
Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial
Timo Vesikari, Jiri Beran, Serge Durviaux, et al.
The Pediatric Infectious Disease Journal
|
May 10, 2011
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants
Timo Vesikari, Jason C Martin, Charles L Liss, et al.
Human Vaccines & Immunotherapeutics
|
March 25, 2017
Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa
Timo Vesikari, Luis Rivera, Tiina Korhonen, et al.
Human Vaccines & Immunotherapeutics
|
September 19, 2019
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
Timo Vesikari, Miia Virta, Seppo Heinonen, et al.
The Pediatric Infectious Disease Journal
|
May 5, 2011
Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age
Timo Vesikari, Aino Karvonen, Tiina Korhonen, et al.
Vaccine
|
October 16, 2007
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres
Clare L Hibbert, Pedro A Piedra, Kimmie K McLaurin, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2010
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months
Timo Vesikari, Aino Karvonen, Niklas Lindblad, et al.
Lancet (London, England)
|
January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
Timo Vesikari, Susanna Esposito, Roman Prymula, et al.
Page
of 22